SCHEMBL3524149

SCHEMBL3524149

COC(=O)CCCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1ccc2nc(C)sc2c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.47
ALDH1A1 P00352 3/20 0.47
PKM P14618 2/20 0.47
HTT P42858 4/20 0.44
GPR55 Q9Y2T6 1/20 0.44
MAPK1 P28482 2/20 0.44
SMN1; SMN2 Q16637 6/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 2/20 0.43
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43
P2RX3 P56373 2/20 0.41
CYP2C9 P11712 1/20 0.41
NOD2 Q9HC29 1/20 0.41
HPGD P15428 1/20 0.40
KDM4E B2RXH2 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3528051 0.93 ALDH1A1 (0.45) LMNAALDH1A1PKMHTTGPR55
SCHEMBL3529515 0.91 PPARG (0.42) LMNAALDH1A1PKMHTTSMN1; SMN2
SCHEMBL3524989 0.89 AKT1 (0.50) MAPK1HPGDKDM4E
SCHEMBL3525543 0.86 ALDH1A1 (0.44) LMNAALDH1A1PKMHTTMEN1
SCHEMBL3521677 0.86 CYP3A4 (0.43) LMNAALDH1A1PKMHTTSMN1; SMN2
SCHEMBL3528328 0.85 TSHR (0.41) ALDH1A1MAPK1MAPTPPARGHPGD
SCHEMBL3523578 0.84 AKT1 (0.51) MAPK1MEN1KMT2AHPGDKDM4E
SCHEMBL3527869 0.84 CCR9 (0.40) LMNAALDH1A1PKMMEN1KMT2A
SCHEMBL3522354 0.83 LMNA (0.46) LMNAALDH1A1PKMHTTMAPK1
SCHEMBL3525579 0.83 CCKBR (0.42) MEN1KMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP LMNA 849/4885ALDH1A1 1607/4885PKM 728/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG LMNA 1980/4885ALDH1A1 1453/4885PKM 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.